Back to search

Article

Integrating AI-MIDD with Mechanistic Erythropoietin Modeling: A Digital-Twin Framework for Optimizing ESA Therapies

2025-11-13

Abstract excerpt

Erythropoiesis-stimulating agents (ESAs) remain a mainstay for anemia therapy, yet variability in response and emerging resistance mechanisms limit their effectiveness. We developed a hybrid AI-MIDD (Model-Informed Drug Development) and Quantitative Systems Pharmacology (QSP) platform and applied it for integrating mechanistic signaling (EPO–EpoR–JAK2/STAT5–SOCS3/CIS) with metabolic (mTOR), iron-homeostatic (hepci...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
e6b3ae10-2f14-5468-8ad1-ca39d6cbdd3d
DOI
10.1101/2025.11.12.688044
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
Integrating AI-MIDD with Mechanistic Erythropoietin Modeling: A Digital-Twin Framework for Optimizing ESA TherapiesDOI 10.1101/2025.11.12.688044
Select a neighboring publication to make it the new centre.